Edit |   |
Antigenic Specificity | S100A8, Human |
Clone | REA917 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | allophycocyanin (APC) conjugate |
Size | 30 tests in 60 µL |
Concentration | 1:50 |
Applications | Intracellular flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | S100A8 Antibody, anti-human, APC, REAfinity™. Clone REA917 recognizes the calcium- and zinc-binding protein S100A8, also known as migration inhibitory factor-related protein 8 (MRP-8), calprotectin, or calgranulin-A. S100A8 is mainly expressed in myeloid cells, e.g., monocytes, macrophages, and granulocytes and upregulated in different tumors, e.g., in skin, breast, colon, pancreatic, bladder, and ovarian malignancies. S100A8 is involved in the regulation of inflammatory processes and immune response and plays a role in antimicrobial, cytostatic, and chemotactic activities. | Additional information: Clone REA917 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | Calgranulin A, Calprotectin, S100A8, CAGA, CFAG, MRP8 |
Gene, Accession # | Gene ID: 6279 |
Catalog # | 130-115-354 |
Price | $142 |
Order / More Info | S100A8, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Rammes, A. et al. (1997) Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem. 272 (14): 9496-9502. | Viemann, D. et al. (2005) Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 105 (7): 2955-2962. | Ehrchen, J. M. et al. (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86 (3): 557-566. |